Vantage logo

Pepgen aims to overtake Sarepta

Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.

Vantage logo

Sarepta loses its Momentum

A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.